Blueprint Medicines (BPMC) | Stock Overview & Key Data
Blueprint Medicines Performance Comparison
Stock Range
Today's Range
Low: $129.46
High: $129.46
on July 18, 2025
52 Week Range
Low: $73.04
High: $129.65
on April 9, 2025
on July 16, 2025
All-Time High: $129.65 on July 16, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$8.4B
EPS
-2.51
P/E Ratio (TTM)
-120.99
Forward P/E
-137.72
P/B Ratio
24.43
PEG Ratio
-137.72
Div. Yield
N/A
ROE
-47.71%
Beta
0.833
Debt to Equity
208.50
Financial Highlights
Profitability
Gross Margin
98.12%
Operating Margin
-27.50%
Profit Margin
-27.70%
Returns and Earnings
Return on Assets (TTM)
-9.75%
Return on Equity (TTM)
-47.71%
EBITDA
$-158.4M
Net Income (TTM)
$-155.7M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$8.82
Quarterly Revenue Growth (YoY)
55.50%
Quarterly Earnings Growth (YoY)
-99.40%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Blueprint Medicines BPMC | 8.37B Mid-cap | 0.12% | 1.05% | 53.79% | 15.63% | 48.46% | 12.60% | 149.54% | 73.38% |
| Vertex VRTX | 121.28B Large-cap | -17.78% | -18.24% | -13.61% | -19.96% | -7.43% | -17.68% | 30.94% | 44.28% |
| Regeneron REGN | 60.39B Large-cap | 2.63% | 4.03% | -0.20% | -21.15% | -21.73% | -50.93% | -11.70% | -9.38% |
| BridgeBio Pharma BBIO | 8.68B Mid-cap | -2.79% | 5.63% | 28.28% | 44.27% | 62.94% | 88.09% | 296.12% | 61.06% |
| Bio-Techne TECH | 7.92B Mid-cap | -8.37% | -2.70% | 2.87% | -31.12% | -29.84% | -30.51% | -47.46% | -23.58% |
| Roivant Sciences ROIV | 7.94B Mid-cap | 1.67% | 7.54% | 3.40% | 6.06% | -4.39% | 4.77% | 166.59% | 17.44% |
Ownership & Short Interest
Insider Ownership
0.88%
Institutional Ownership
109.19%
Shares Short
3M
Short Ratio
0.62
Short % of Shares Outstanding
5.45%
Average 10-Day Volume
6M
Average 90-Day Volume
4M
Blueprint Medicines Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Blueprint Medicines would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is BPMC's 52-week high and low?
- In the last 52 weeks, Blueprint Medicines reached a high of $129.65 (on July 16, 2025) and a low of $73.04 (on April 9, 2025).
- What is the market cap and P/E ratio for BPMC?
- Curious about Blueprint Medicines's size and valuation? Its market capitalization stands at 8.37B. When it comes to valuation, the P/E ratio (trailing twelve months) is -120.99, and the forward P/E (looking ahead) is -137.72.
- Does BPMC pay dividends? If so, what's the yield?
- As for dividends, Blueprint Medicines isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Blueprint Medicines's main competitors or similar companies to consider before investing?
When looking at Blueprint Medicines, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX121.28B Healthcare Biotechnology -17.68% 30.94% Regeneron
REGN60.39B Healthcare Biotechnology -50.93% -11.70% BridgeBio Pharma
BBIO8.68B Healthcare Biotechnology 88.09% 296.12% Bio-Techne
TECH7.92B Healthcare Biotechnology -30.51% -47.46% Roivant Sciences
ROIV7.94B Healthcare Biotechnology 4.77% 166.59% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Blueprint Medicines Corp.? (e.g., ROE, Debt/Equity)
- To get a sense of Blueprint Medicines's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -47.71%, the Debt to Equity ratio from the most recent quarter is 208.50, and its Gross Profit Margin stands at 98.12%.
- What is the recent revenue and earnings growth for BPMC?
- Looking at Blueprint Medicines's growth, its revenue over the trailing twelve months (TTM) was $562M. Compared to the same quarter last year (YoY), quarterly revenue grew by 55.50%, and quarterly earnings saw a YoY growth of -99.40%.
- How much of BPMC stock is held by insiders and institutions?
- Wondering who owns Blueprint Medicines stock? Company insiders (like executives and directors) hold about 0.88% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 109.19%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.